11:44 AM EST - Neptune Technologies & Bioressources Inc. : announced financial results for the quarter ended August 31, 2009. Net loss attributable to Neptune nutraceutical business was $1.49 million or $0.04 per share compared to a loss of $376,000 or $0.01 per share last year. Revenue was $1.352 million compared to $2.325 million prior year. Neptune, Acasti and Neurobiopharm consolidated net loss was $2.112 million or $0.06 per share compared to a loss of $598 thousand or $0.016 per share prior year. Total revenue was $1.37 million compared to $2.365 million last year. Neptune Technologies & Bioressources Inc.
shares V.NTB are trading down $0.08 at $2.04.
